الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 173 |  |  |
| | | from | 173 | | |
Abstract
The heart is considered an essential cone-shaped muscular organ with very important functions. The heart is exposed to numerous forms of injury, which may then stimulating different heart disorders. Doxorubicin (DOXO) is one of the anthracycline antibiotics. It has good anticancer activity against a wide spectrum of tumors. Its full potential as an anticancer agent has not been reached because of a dose-limiting toxicity on liver, kidney and particularly the heart. Rifampicin (Rif) is a semisynthetic antibiotic and clinically utilized for treating bacterial infections. Beside its antibacterial effect, it has showed a protective effect against liver injury as hepatic protector. The aim of this study was to investigate the possible cardioprotective effect of Rif on Doxo-induced cardiomyopathy in male albino mice. To achieve our goals, seventy male mice were divided into seven groups of ten animals each as follows: Control group: contains normal mice. Doxo (cardiomyopathy; cardiac toxicity) group: mice received Doxo (i.p.)for a cumulative dose of 15 mg/kg for 14 days. Doxo+Rif 0.107 group: male mice received i.p. injection of rifampicin daily (0.107 mg/kg/day) for 14 days concomitant with doxorubicin injection. Doxo+Rif 0.214 group: male mice received i.p. injection of rifampicin daily (0.214 mg/kg/day) for 14 days concomitant with doxorubicin injection. Rif 0.107 group: male mice received i.p injection of rifampicin once a day (0.107 mg/kg/day) for 14 days. Rif 0.214 group: male mice received i.p injection of rifampicin once a day (0.214 mg/kg/day) for fourteen days. Vehicle group: male mice received i.p injection of used solvent once a day for fourteen days. In conclusion, our study results show that rifampicin has been considered a cardioprotective drug against Doxo-induced cardiomyopathy.